2-Isopropyl-1,3-Thiazole-4-Carboxylic Acid

Activation at Sub‑Ambient Temperatures Sustains Acyl Chloride Integrity for Ritonavir Side‑Chain Assembly

On a production line for the antiretroviral ritonavir, the batch charging of 2‑isopropyl‑1,3‑thiazole‑4‑carboxylic acid into a 2000 L glass‑lined reactor jacket‑chilled to ‑10 °C represents the first unit operation in a sequence where the exotherm of acid chloride generation must remain decoupled from solvent reflux. The carboxylic acid is slurried in dichloromethane and treated stoichiometrically with thionyl chloride (1.05‑1.15 molar equivalents, determined by inline FT‑IR tracking of the carbonyl shift from 1713 cm⁻¹ to 1785 cm⁻¹) under catalytic dimethylformamide (0.5 mol%). Reaction calorimetry data from a Mettler Toledo RC1e simulation indicate a heat release of ‑135 kJ per mole of thionyl chloride fed; jacket control response must maintain the internal temperature at or below ‑5 °C to suppress formation of the dimeric anhydride impurity (detected at RRT 1.32 by the validated HPLC method). Once conversion exceeds 99.5 % (IPC), the resulting 2‑isopropyl‑1,3‑thiazole‑4‑carbonyl chloride is coupled with the remaining (2S,3S,5S)‑5‑amino‑2‑(N,N‑dibenzyl)amino‑1,6‑diphenyl‑3‑hexanol fragment in a separate vessel to form the amide backbone. The process, governed by current Good Manufacturing Practice per ICH Q7 and subject to component testing as defined in 21 CFR 211.84, incorporates a mandatory hold‑time study for the isolated acid chloride solution (≤ 8 hours at ‑5 ± 2 °C) due to observed moisture‑driven hydrolysis yielding back the parent acid and reducing coupling efficiency. Downstream, the protected amide undergoes catalytic hydrogenolysis over 10 % Pd/C (Type 487, Johnson Matthey) in tetrahydrofuran at 3.5 bar hydrogen and 45‑50 °C to remove benzyl protecting groups, followed by recrystallization from isopropanol/water to afford ritonavir free base conforming to USP monograph specifications. The terminal article is dried under vacuum (≤ 20 mbar, 45 °C) to a loss on drying of ≤ 0.3 % and packaged as the antiretroviral active pharmaceutical ingredient with a typical batch size of 180‑220 kg. Potential mutagenic impurity concern arising from sulfonate esters in the later salt‑formation step necessitates compliance with the ICH M7 control option 3, with periodic purge factor verification using laboratory‑scale doping runs. A documented incompatibility exists with triethylamine‑based scavengers in the work‑up of the acid chloride solution: residual tertiary amine generates quaternary ammonium salts that partition unpredictably during the aqueous bicarbonate wash and reduce yield by 2‑4 percentage points.

Why Does Residual Ethyl Acetate Content in the Carboxylic Acid Feedstock Influence Cobicistat Reductive Amination Yield?

The preparation of cobicistat, a pharmacokinetic enhancer devoid of intrinsic antiviral activity, relies on the conversion of 2‑isopropyl‑1,3‑thiazole‑4‑carboxylic acid into its corresponding N,O‑dimethylhydroxylamide (Weinreb amide) before reductive transformation to the aldehyde that is coupled with the core pyrrolidine fragment. Experience on pilot‑scale campaigns (50‑100 kg input per batch) has shown that residual ethyl acetate carried over from the supplier’s purification step—even at levels within the ICH Q3C Class 3 limit of ≤ 5000 ppm—acts as a latent catalyst poison during the subsequent hydrogenolysis step that removes the N‑benzyl protection from the fully assembled cobicistat backbone. The ester is believed to undergo hydrogenolysis on the palladium‑on‑carbon catalyst bed, generating ethanol and acetic acid; the latter protonates the N‑benzylamine portion of the intermediate and retards debenzylation kinetics to the extent that a reaction initially completed at 3.0 bar hydrogen in 6 hours extends to 14‑16 hours, increasing the level of des‑benzyl phenol impurity (identity confirmed by LC‑HRMS with mass accuracy < 3 ppm) by 0.8‑1.2 area%. To mitigate this, the incoming carboxylic acid is subjected to a vacuum‑drying protocol (≤ 5 mbar, 40 °C, minimum 8 hours) immediately upon warehousing release; the limit for ethyl acetate is tightened to ≤ 800 ppm on the certificate of analysis, a value validated through multivariate analysis of ten consecutive GMP campaigns. The Weinreb amide synthesis itself is conducted in 2‑methyltetrahydrofuran at ‑10 ± 3 °C using 1.1 equivalents of N,O‑dimethylhydroxylamine hydrochloride and isobutyl chloroformate (1.05 eq.) alongside N‑methylmorpholine (2.4 eq.) as acid scavenger; the addition is calibrated so that the internal temperature never exceeds ‑5 °C during the anhydride formation phase. After aqueous work‑up and solvent switch to tetrahydrofuran, the aldehyde reduction is performed with Red‑Al^® (sodium bis(2‑methoxyethoxy)aluminum hydride, 1.15 equivalents) at ‑30 to ‑25 °C, immediately quenched into a pre‑cooled Rochelle’s salt solution to prevent over‑reduction to the alcohol. The aldehyde solution must be used within 12 hours of generation or stored under argon at ‑20 °C to limit oxidative degradation (aldehyde‑to‑acid transformation monitored by TTC‑stained HPTLC). The final reductive amination with the pyrrolidine‑containing intermediate utilises sodium triacetoxyborohydride (1.4 eq., charged in 4 equal portions) in dichloromethane at 20‑25 °C. The terminal article, cobicistat, is crystallised from acetone/water and sieved to a particle size d(v, 0.9) ≤ 150 µm for direct use in fixed‑dose combination tablets manufactured under 21 CFR Part 210. Throughout, compliance with ICH Q11 on starting material justification is documented by an impurity fate and purge study linking seven potential process impurities back to the thiazole acid input, confirming removal factors below the threshold of toxicological concern.

The azeotropic dehydration of the carboxylic acid‑derived intermediate with (4‑chlorophenyl)methoxyacetic acid in toluene at reflux (approximately 111 °C) forms the central amide bond of the fungicide ethaboxam before the vapour temperature at the Dean‑Stark trap stabilises and the collected water volume matches the stoichiometric prediction (18.0 ± 0.3 mL per mole of water expected on a 20‑mol scale). During the initial 60‑75 minutes of this condensation, the reaction mass remains a thin suspension; at a water removal of ≥ 85 % of theory, the mixture thickens abruptly due to precipitation of the product in a meta‑stable kinetically favoured polymorphic form, which must be converted to the thermodynamically stable monohydrate by tempering the slurry at 85‑90 °C for 2 hours prior to cooling to 10 °C. Failure to implement this ripening step results in a filter cake that compacts during centrifugal isolation (900 rpm, 800 mm basket diameter), blinding the filter cloth and elevating moisture content to ≥ 12 % w/w, retarding the subsequent drying step in the conical paddle drier (50 °C, ≤ 30 mbar vacuum) and requiring reprocessing.

The original 2‑isopropyl‑1,3‑thiazole‑4‑carboxylic acid is reduced to the corresponding primary amine via a two‑stage sequence—first conversion to the primary amide via the mixed anhydride with isobutyl chloroformate in tetrahydrofuran at ‑15 °C, followed by Hofmann rearrangement using sodium hypochlorite (13 % active chlorine, 1.05 equivalents) and aqueous sodium hydroxide at 0‑5 °C—to furnish 1.0 molar equivalent of the thiazole‑4‑methanamine fragment that is telescoped without isolation into the azeotropic coupling. In this configuration, the addition ratio of the acid‑derived amine to the (4‑chlorophenyl)methoxyacetyl chloride intermediate (generated in situ from the acid and thionyl chloride at 50 °C) is kept at 1.00 : 1.05 to ensure complete consumption of the costly thiazole component; IPC by GC (DB‑5 column, 15 m × 0.25 mm I.D.) is triggered when the top phase of the toluene distillate clears. The crude ethaboxam is dissolved in hot methanol and filtered through a 0.5 µm cartridge before controlled cooling crystallisation (linear ramp ‑0.3 °C/min) to yield the technical material with a melting onset of 129.8‑131.2 °C (DSC, 10 °C/min) and assay ≥ 97.0 % (HPLC, area normalisation). Registration‑supporting toxicology batches are executed under OECD GLP principles, and the five‑batch analysis is submitted to the FAO/WHO Joint Meeting on Pesticide Specifications to establish the specification 780/TC. Effluent from the aqueous hypo‑chlorite stream is quenched with sodium bisulphite to reduce Active Chlorine to < 0.1 mg/L before discharge, in line with the site’s ISO 14001 environmental permit. The terminal article is formulated as a 10 % SC (suspension concentrate) through wet milling on a horizontal bead mill (zirconia beads 0.6‑0.8 mm) to a particle size d(0.5) < 2 µm, stabilised with 2.5 % w/w non‑ionic block‑copolymer dispersant and 0.15 % w/w xanthan gum thickener; packaged volumes range from 1 L HDPE containers to 200 L poly‑lined steel drums for export.

Amide Forming Reactions on Solid Phase: Derivatisation of 2‑Isopropyl‑1,3‑thiazole‑4‑carboxylic Acid in DNA‑Encoded Library Synthesis

In automated DEL platforms executing split‑and‑pool chemistry on macroporous polystyrene‑PEG resins (TentaGel® S RAM, loading 0.25 mmol/g), 2‑isopropyl‑1,3‑thiazole‑4‑carboxylic acid is activated with HATU (2.5 equiv.) and N,N‑diisopropylethylamine (5.0 equiv.) in anhydrous N‑methyl‑2‑pyrrolidone and added as a 0.2 M solution in 10‑fold molar excess relative to the resin‑bound amine to drive acylation to completion within 45 minutes at 25 °C on a plate shaker set to 1200 rpm orbital mixing. The necessity for such high excess stems from the competing solvolysis of the activated ester by adventitious water remaining in the resin pores after lyophilisation—a phenomenon confirmed by quantitative ¹⁹F‑NMR of the cleavage cocktail when a fluorinated internal standard is spiked. After three cycles of washing with the solvent, Fmoc deprotection with piperidine ( 20 % v/v in DMF, 15 min) exposes a secondary amine for the next cycle. The carboxylic acid used in this context must pass a double‑threshold release test: LCMS purity ≥ 95 % (UV‑254 nm) and absence of polymerisation inhibitors such as phenolic antioxidants that quench photoredox‑mediated on‑DNA reactions. Contract service providers performing these transformations operate under a quality system aligned with ISO 9001:2015 and adhere to the compound handling guidelines of the ACS Green Chemistry Institute for small‑scale synthesis; however, Good Manufacturing Practice is not invoked for early‑discovery libraries. The terminal output consists of DNA‑tagged encoded compounds where the thiazole‑4‑carboxamide moiety forms the central B‑block in a 3‑cycle library designed to explore ATP‑competitive kinase hinge binders, and all members are registered as non‑assayable support samples with a mass recovery criterion of ≥ 50 nmol per well quantified by Nanodrop UV at 260 nm.

Reference Material Certification Under ISO 17034 for Spiking in Impurity Profiling by UPLC‑MS/MS

Pharmacopoeial monographs for ritonavir and cobicistat drug substances include a chromatographic purity method in which 2‑isopropyl‑1,3‑thiazole‑4‑carboxylic acid serves as the marker for Process Impurity A (unreacted starting material carry‑over) at a reporting threshold of 0.05 %. To prepare the certified reference standard, a highly purified batch of the acid (zone‑refined in a 12‑zone vertical purification train under argon flow, advancing 4 mm/h) is milled with a cryogenic pin mill (‑140 °C inlet nitrogen, 80 m/s tip speed) to a particle size d(0.9) ≤ 20 µm and homogenised in a V‑type blender for 45 minutes at 20 rpm. Homogeneity is demonstrated by taking 10 increments following a stratified random sampling plan and assaying each by qNMR against a maleic acid internal standard traceable to NIST SRM 350b; the lot is accepted only if the standard deviation of the purity values is ≤ 0.10 % (absolute). Certification is performed under ISO 17034:2016 and the measurement value is assigned via a combination of mass balance (100 % minus organic impurities by LC‑CAD, volatile impurities by TGA‑FTIR, and non‑volatile residue by combustion ion chromatography) and the qNMR result. The assigned purity of a typical batch is 99.83 ± 0.12 % (k=2). The certified reference material is bottled in 100 mg amber Type I glass vials under argon and shipped at 2‑8 °C with a documented shelf‑life of 48 months. In the receiving QC laboratory, a 0.1 mg/mL stock solution in acetonitrile is prepared daily and diluted for the system suitability solution that must exhibit a signal‑to‑noise ratio ≥ 10:1 at the reporting limit on the UPLC‑MS/MS platform (Waters ACQUITY H‑Class coupled to Xevo TQ‑S micro, MRM transition 186.2 → 142.0). The spiking recovery at the 0.05 % (w/w) level in a placebo tablet matrix was validated at 97.4‑101.1 % (mean 99.2 %, RSD 1.9 %, n=9) according to ICH Q2(R2) analytical procedures and methods validation requirements, and the standard is therefore included as the key component of the impurity reference kit for submissions to US FDA and EMA marketing authorisation applications.